New approaches to front-line therapy in multiple myeloma patients aged over 60 years

JF San-Miguel; MV Mateos

doi:10.4081/hmr.v2i7.406

Authors

High dose therapy followed by autologous stem cell support (ASCT) represents the standard of care for younger myeloma patients. However, half of MM patients are >70 years at diagnosis and other have comorbidetes which preclude ASCT. For more than 30 years Melphalan-Prednisone (MP) has been the standard treatment for elderly MM patients, although the response rate (RR) is only 40-50% and complete responses (CR) are rare. Median duration of response to MP is 1.5 years and median O.S is 2-3 years.

Supporting Agencies

San-Miguel, J., & Mateos, M. (2009). New approaches to front-line therapy in multiple myeloma patients aged over 60 years. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.406

Download Citation

Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations